MedTrace Logo

Chronic Obstructive Pulmonary Disease, Quality of Life, COPD Assessment Test, Nepal, Dyspnea, Spirometry

NCT07261813 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2025-12-03

No results posted yet for this study

Summary

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. The study "Quality of life among people living with Chronic Obstructive Pulmonary Disease- visiting spirometry center of Tribhuvan University Teaching Hospital, Kathmandu Nepal" aims to assess the quality of life (QOL) of COPD patients and the factors affecting it.

A cross sectional study will be performed among the patients visiting Spirometry center of Tribhuvan University Teaching Hospital, Kathmandu Nepal using Convenience Sampling. Ethical approval will be obtained from Institutional Review Board (IRB) of TUTH and written/verbal consent for data collection will be obtained from Teaching hospital authority as well as the respondents. CAT questionnaire will be used to assess quality of life and the Medical Research Council questionnaire will be used to assess the severity of dyspnea. Data management and analysis will be conducted through Statistical Package for Social Sciences (SPSS) version 26.0.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Quality of Life

Interventions

OTHER

Evaluation of Quality of life in COPD patients

This study does not involve a clinical intervention. Instead, it focuses on evaluating Quality of life of COPD patient using the COPD Assessment Test (CAT). It is a validated, patient-completed questionnaire designed to assess the impact of Chronic Obstructive Pulmonary Disease (COPD) on a patient's health status. It consists of eight simple questions, each scored from 0 to 5, covering symptoms such as cough, sputum production, chest tightness, breathlessness, activity limitation, confidence leaving home, sleep quality, and energy levels. The total score ranges from 0 to 40, with higher scores indicating a greater impact of COPD on the patient's daily life. A score of 0-10 suggests a low impact, 11-20 a medium impact, 21-30 a high impact, and 31-40 a very high impact. The CAT is easy to administer, typically taking less than two minutes to complete, and provides clinicians with a standardized way to monitor disease progression and evaluate treatment effectiveness.

Sponsors & Collaborators

  • Institute of medicine, Maharagjung medical campus

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-01-01
Completion
2026-01-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07261813 on ClinicalTrials.gov